Skip to content
healthcare.dev
Get a free key

Cinryze

NDC 42227-081, HUMAN C1-ESTERASE INHIBITOR, injection, powder, lyophilized, for solution, from Takeda Pharmaceuticals America, Inc..

Product NDC
42227-081
Status
Listed
Labeler
Takeda Pharmaceuticals America, Inc.
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS
Product type
PLASMA DERIVATIVE
Marketing category
BLA
Application
BLA125267
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/42227-081 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • HUMAN C1-ESTERASE INHIBITOR500 [iU]/5mL

Pharmacologic classes

Decreased Vascular Permeability [PE]; Human C1 Esterase Inhibitor [EPC]; Kallikrein Inhibitors [MoA]

Package NDCNDC-11Package
42227-081-01422270081015 mL in 1 VIAL, SINGLE-USE (42227-081-01)

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.

Use it

Look up 42227-081 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/42227-081 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 42227-081. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Get a free keyNDC docsConnect the MCP server

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.